Summary : IMCIVREE now available for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Category:
Active Pharmaceutical Ingredients (API)
-
-
Active Pharmaceutical Ingredients (API)CompaniesGlobal MarketPAXLOVIDPfizer
After Watershed Year, Pfizer Expects Revenue to Top $98B in ’22
by adminby adminSummary : Pfizer Chief Executive Officer Albert Bourla called 2021 a watershed year for the company. It posted $81.3 billion in revenue…
-
Active Pharmaceutical Ingredients (API)CompaniesGlobal MarketPAXLOVIDPfizer
COVID-19: EMA recommends conditional marketing authorisation for Paxlovid
by adminby adminSummary : EMA’s human medicines committe has recommended granting conditional marketing authorisation for the oral antiviral medicine Paxlovid (PF-07321332 / ritonavir) for…
-
Maribavir
Takeda’s LIVTENCITY (Maribavir) Approved by U.S. FDA as the First and Only Treatment of Post-Transplant Cytomegalovirus (CMV), that is Resistant to other Antiviral Drugs.
by adminby adminSYNOPSIS: Takeda announced that U.S. FDA Approved LIVTENCITY (Maribavir) as the First and Only Treatment for People Ages 12 or older and…
-
CompaniesPfizerTofacitinib
Pfizer’s XELJANZ® (Tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
by adminby adminAbstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…
-
Nelarabine
Zydus Cadila receives USFDA Final Approval for Nelarabine Injection a Therapeutically Generic Version of Arranon injection.
by adminby adminKEYPOINTS: Zydus Cadila has received final approval from the US FDA to market Nelarabine injection 250MG/50ML in the United States. Zydus Pharmaceuticals…
-
Diroximel Fumarate
The European Commission Grants Marketing Authorization for VUMERITY® (Diroximel Fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis.
by adminby adminSYNOPSIS: VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s…
-
Mepolizumab
GlaxoSmithKline`s Nucala (Mepolizumab) gets European Approval for use in Three Additional Eosinophil-driven Diseases.
by adminby adminKEYPOINTS: GlaxoSmithKline (NYSE:GSK) announces that the European Commission has approved Nucala (Mepolizumab), a monoclonal antibody that targets interleukin-5, for use in three…
-
Active Pharmaceutical Ingredients (API)Risankizumab
European Commission approves AbbVie’s Skyrizi (Risankizumab) to Treat Adults with Active Psoriatic Arthritis.
by adminby adminKEYPOINTS: AbbVie announces that the European Commission (EC) has approved SKYRIZI (Risankizumab, 150 mg, subcutaneous injection at week 0, week 4, and…
-
Active Pharmaceutical Ingredients (API)Insulin
Biocon Biologics and Viatris launch Interchangeable Biosimilars SEMGLEE and Insulin Glargine Injection in US.
by adminby adminKEYPOINTS: Biocon Biologics and Viatris Inc have launched Semglee (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an…
Newer Posts